$KRRO

Aiyar Ram sold $197K of KRRO

Aiyar Ram (President and CEO) sold 15,152 shares of Korro Bio, Inc. (KRRO) at $12.98 ($0.20M total) on 2026-05-29.

Original reporting
SEC EDGAR · Aiyar Ram
Published Jun 2, 2026, 11:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 11:03 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$KRRO
Neutral
medium confidence
Mentioned
$KRRO
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KRRONeutralLow
01

Why it matters

The disclosure provides incremental sentiment information (insider reducing exposure) but no new operational or clinical catalyst.

02

Market read

Traders may briefly reassess sentiment around KRRO, but the event alone is unlikely to drive a sustained repricing without accompanying fundamental updates.

03

What to watch

The filing does not state motivation, and the post-sale holdings (74,848 shares) suggest the CEO did not exit the position entirely.

Relevance 6/10Novelty 6/10Timing: Filed pre-market today (2026-06-02) for a sale executed 2026-05-29

Background

This is an SEC Form 4 insider transaction: CEO/Aiyar Ram sold shares of Korro Bio, Inc. (KRRO) on 2026-05-29; the report was filed 2026-06-02.

Company-level read

Ticker impact

$KRRONeutralMedium confidence
Context

Korro Bio CEO sold 15,152 shares in an open-market transaction, disclosing a direct insider ownership reduction at $12.98/share.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically fades unless followed by additional disclosures.

Evidence & confidence

The filing is a routine SEC Form 4 insider sale with no stated reason, and it does not include new company fundamentals (e.g., trial results, guidance, or deals).

Market effects

Minimal; single-company insider sale typically does not reset sector expectations.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for diversification or liquidity needs; the absence of a 10b5-1 plan does not necessarily imply negative fundamentals.

Key entities

  • Korro Bio, Inc.

    Subject of the Form 4 insider sale by its President and CEO.

  • Aiyar Ram

    President and CEO who sold 15,152 shares at $12.98/share.

Related articles

$KRROMed

Korro Bio, Inc. (KRRO): Results of Operations and Financial Condition

Korro Bio, Inc. (KRRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 4 krro-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update — KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical tria